Compare HCA Health Inc (HCA) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Verisign, Inc. — how do they compare? HCA Health Inc trades at $450.18 (market cap $96.35B), while Verisign, Inc. trades at $304.06 (market cap $26.92B). The key difference: HCA Health Inc is far larger — about 3.6× Verisign, Inc.'s market cap, and Verisign, Inc. pays the higher dividend (1.09%). Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and Verisign, Inc. for 123 Days on average.
| HCA | VRSN | |
|---|---|---|
Market Cap | $96.35B | $26.92B |
Volume | 1,079,453 | 1,921,402 |
Sector | Health | Technology |
52-Week High | $545.13 | $310.00 |
52-Week Low | $361.32 | $211.49 |
Typical Hold Time | 76 Days | 123 Days |
Enterprise Value | $146.88B | $28.23B |
Dividend Yield | 0.7% | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $451.09, up 2.71% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q4 2025 and Q1-Q2 2026 exceeding expectations, supported by robust revenue growth from $70.6B in 2024 to $75.6B in 2025. Valuation metrics remain attractive with P/E of 14.92 and P/S of 1.31, while technical indicators signal bullish momentum above key support levels.
The outlook remains positive with 63% analyst buy ratings and $461.12 consensus target, though legal investigations and high debt levels pose risks. Revenue growth and operational efficiency provide upside potential, but investors should monitor regulatory developments and debt management closely given the 80.9% debt-to-asset ratio in 2025.
VeriSign (VRSN) trades at $303.74, up 3.24% today, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 49.77% net income margin and consistent revenue growth, reaching $1.66B in 2025. Recent news includes an upcoming Q3 2026 earnings call and insider selling by the CEO, while institutional buying from firms like BlackRock signals confidence. A class-action antitrust lawsuit filed in September 2026 poses a regulatory risk.
The investment outlook is positive, driven by analyst consensus favoring a buy rating with a $348 price target, implying 15% upside. Key opportunities include AI-driven domain growth and a pending .com price increase. Risks involve the antitrust litigation, competitive pressures, and reliance on domain registry revenues. Earnings momentum is mixed, with Q2 2026 missing estimates but Q1 beating expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
